Relationships between Prostate-Specific Antigen, Prostate Volume, and Components of Metabolic Syndrome in Healthy Korean Men

다국어 초록 (Multilingual Abstract)

Purpose: Metabolic syndrome (MS) plays a potential role in the etiology of benign prostatic hyperplasia (BPH). Recent studies have reported on an association between MS and BPH. However, there has been no consensus on recent results. This study was conducted to evaluate the associations among prostate-specific antigen (PSA), prostate volume (PV), and metabolic components in men who visited our health promotion center.
Materials and Methods: During the period from January 2005 to December 2010, 521 consecutive men (age range, 40 to 70 years) who underwent transrectal ultrasonography were enrolled in this retrospective study. The health screening program includes blood pressure, body measurements (height, weight, waist circumference, body mass index), biochemical analysis (serum glucose, total cholesterol, triglycerides, high-density and low-density lipoprotein cholesterol, fasting plasma glucose, tumor markers), stool and urine analysis, and a detailed clinical examination.
Results: The serum PSA level and PV were significantly higher in patients with MS than in patients without MS, retrospectively (p＜0.001, p＜0.001). Patients with more than one metabolic component were significantly more likely to have a larger PV and higher serum PSA level. The serum PSA level and PV were increased in a similar manner with the increasing sum of MS components (p＜0.0001, p＜0.0001).
Conclusions: The MS components were associated with larger PV and higher serum PSA level. Therefore, each MS component could be an important factor in BPH development and management.

참고문헌 (Reference)

1 Berry SJ, "The development of human benign prostatic hyperplasia with age" 132 : 474-479, 1984

2 Ozden C, "The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia" 51 : 199-203, 2007

3 Baillargeon J, "The association of body mass index and prostate-specific antigen in a population-based study" 103 : 1092-1095, 2005

4 Jeong IG, "The Association of Metabolic Syndrome and Its Components with Serum Prostate-Specific Antigen Levels in a Korean-Screened Population" AMER ASSOC CANCER RESEARCH 19 : 371-380, 2010

5 Giovannucci E, "Stampfer MJ, et al. Obesity and benign prostatic hyperplasia" 140 : 989-1002, 1994

6 Golomb E, "Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats" 21 : 58-64, 2000

7 Roehrborn CG, "Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia" 53 : 581-589, 1999

8 Hochberg DA, "Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia" 45 : 315-319, 2000

9 Matsuda T, "Relation between benign prostatic hyperplasia and obesity and estrogen" 52 : 291-294, 2004

10 Mochtar CA, "Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia" 44 : 695-700, 2003

11 Bosch JL, "Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism" 27 : 241-249, 1995

12 Bosch RJ, "Pathogenesis of benign prostatic hyperplasia" 20 (20): 27-30, 1991

13 Becker S, "Obesity related hyperinsulinaemia and hyperglycaemia and cancer development" 115 : 86-96, 2009

14 Eom CS, "Metabolic syndrome and accompanying hyperinsulinemia have favorable effects on lower urinary tract symptoms in a generally healthy screened population" 186 : 175-179, 2011

15 Issa MM, "Medical therapy for benign prostatic hyperplasia: present and future impact" 13 (13): 4-9, 2007

16 Mongiu AK, "Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity" 10 : 247-253, 2009

17 DeFronzo RA, "Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease" 14 : 173-194, 1991

18 Vikram A, "Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia" 70 : 79-89, 2010

19 Hammarsten J, "Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia" 39 : 151-158, 2001

20 Lee C, "Etiology of benign prostatic hyperplasia" 22 : 237-246, 1995

21 Hammarsten J, "Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia" 1 : 157-162, 1998

22 Hammarsten J, "Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer" 13 : 47-55, 2004

23 Hammarsten J, "Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia" 8 : 29-36, 1999

24 Hammarsten J, "Calculated fast-growing benign prostatic hyperplasia: a risk factor for developing clinical prostate cancer" 36 : 330-338, 2002

25 Ziada A, "Benign prostatic hyperplasia: an overview" 53 (53): 1-6, 1999

26 Kristal AR, "Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase" 106 : 320-328, 2006

27 Han JH, "Association between serum prostate-specific antigen level, liver function tests and lipid profile in healthy men" BLACKWELL PUBLISHING 102 : 1097-1101, 2008

28 Gupta A, "Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans" 68 : 1198-1205, 2006

29 Rahman NU, "An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat" 100 : 658-663, 2007